Aclaris Therapeutics Inc
SWB:8AT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aclaris Therapeutics Inc
SWB:8AT
|
US |
|
F
|
Fuchs Se
DUS:FPE3
|
DE |
|
Nordic LEVEL Group AB
F:9T2
|
SE |
|
L
|
Linedata Services SA
F:LN4
|
FR |
|
Beijing Geekplus Technology Co Ltd
OTC:BGTCF
|
CN |
|
P
|
Pakistan Oilfields Ltd
KAR:POL
|
PK |
|
Z
|
Zinc Media Group PLC
LSE:ZIN
|
UK |
|
TP ICAP PLC
LSE:TCAP
|
UK |
|
Pagegroup PLC
LSE:PAGE
|
UK |
|
F
|
Feedback Technology Corp
TPEX:8091
|
TW |
Wall St Price Targets
8AT Price Targets Summary
Aclaris Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 8AT is 7.398 EUR with a low forecast of 3.202 EUR and a high forecast of 10.82 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 8AT's stock price target?
Price Target
7.398
EUR
According to Wall Street analysts, the average 1-year price target for 8AT is 7.398 EUR with a low forecast of 3.202 EUR and a high forecast of 10.82 EUR.
What is the Revenue forecast for Aclaris Therapeutics Inc?
Projected CAGR
67%
The compound annual growth rate for Revenue over the next 8 years is 67%.
What is the Gross Profit forecast for Aclaris Therapeutics Inc?
Projected CAGR
174%
The compound annual growth rate for Gross Profit over the next 5 years is 174%.
